Skip to main content

Table 3 Univariable and multivariable analysis of factors associated with ICU admissiona in patients with VRE bloodstream infection

From: Epidemiology, treatment and outcomes of bloodstream infection due to vancomycin-resistant enterococci in cancer patients in a vanB endemic setting

 

ICU admission (n = 13)

No ICU admission

(n = 80)

Univariable odds ratio

95% CI

p-value

Multivariable odds ratio

95% CI

p-value

Age, median (IQR), years

47 (40–63)

58 (43–66)

0.98

0.94–1.01

0.212

   

Male

6 (46%)

43 (54%)

0.74

0.23–2.39

0.612

   

CDS-VRE, median (IQR)

1.9 (1.5–3.6)

1.9 (1.8–3.4)

1.02

0.67–1.55

0.932

   

Hematological malignancy

12 (92%)

69 (86%)

1.91

0.23–16.21

0.552

   

AlloBMT

6 (46%)

18 (23%)

2.95

0.88–9.90

0.080

0.96

0.16–5.96

0.968

Antibiotic days prior to BSI, median (IQR)

20 (18–29)

16 (9–26)

1.03

0.99–1.08

0.163

1.02

0.97–1.08

0.399

ICU admissionb

4 (31%)

25 (31%)

0.98

0.28–3.48

0.972

   

Hypoalbuminemia daysb, median (IQR)

18 (14–30)

17 (9–29)

1.03

0.97–1.09

0.380

   

Mucositis grade, median (IQR)

3 (0–4)

0 (0–2)

1.60

1.11–2.30

0.011

1.81

1.04–3.14

0.036

Polymicrobial BSI

3 (23%)

18 (23%)

1.03

0.26–4.16

0.963

   

Neutropenia at time of BSI

9 (69%)

66 (83%)

0.48

0.13–1.77

0.269

   

Teicoplanin monotherapy

4 (31%)

55 (69%)

0.23

0.06–0.83

0.024

0.14

0.03–0.66

0.013

  1. CDS-VRE score Chronic Disease Score specific to VRE, CKD chronic kidney disease, AML Acute myeloid leukemia, alloBMT allogeneic bone marrow transplant
  2. aICU admission within 48-h of bloodstream infection
  3. bIn 30 days prior to bloodstream infection